Precision medicine opportunity DxTerity focuses on RNA-based immune profiling to understand autoimmune diseases. Potential sales angle: offer advanced molecular profiling services, data analytics support, and integration with clinical workflows to autoimmune clinics and hospitals seeking personalized care solutions.

Lupus expansion Recent partnerships with Lupus Research Alliance and the May 2023 alignment suggest a strategic focus on lupus. Target opportunities include contract research, diagnostic testing partnerships, and payer-ready panels for SLE patient cohorts.

Launchable tests The IFN-1 test for SLE launched in 2022 indicates capability to bring new molecular diagnostics to market. Explore opportunities to co-develop companion tests, expand test menu, and license or co-market innovative assays to nephrology and rheumatology practices.

Ecosystem partnerships Historical collaborations with major players such as Amazon for distribution and Xencor for biotech partnerships show openness to strategic alliances. Opportunities exist in distribution deals, at-home or point-of-care testing channels, and integration with cloud-based health data platforms.

Growth and reach Revenue is in the low millions with a small- to mid-size team. This signals potential for scalable solutions like outsourced lab services, managed services, or VAR/ reseller arrangements to accelerate market penetration in autoimmune diagnostics and precision medicine.